Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment (Q34702608)

4 August 2017

title

Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment (English)

1 reference

4 August 2017

1 reference

Michael F Wempe

1

1 reference

4 August 2017

Peter L Anderson

series ordinal

2

1 reference

4 August 2017

publication date

9 December 2010

1 reference

Drug Metabolism and Disposition

4 August 2017

published in

1 reference

4 August 2017

volume

39

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

522-527

1 reference

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061561

Atazanavir: a review of its use in the management of HIV-1 infection.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061561

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061561

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061561

Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061561

Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061561

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061561

Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061561

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21148251

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21148251

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1124/DMD.110.036178

1 reference

release_hny3wjkgufb7fbaekofoecqsaa

4 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hny3wjkgufb7fbaekofoecqsaa

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

3061561

1 reference

4 August 2017

1 reference